DNA Damage-Inducible Pyocin Expression Is Independent of RecA in
            <i>xerC</i>
            -Deleted Pseudomonas aeruginosa

Bronson, Adam S; Baggett, Nina S; Cabeen, Matthew T.

doi:10.1128/spectrum.01167-22

Cited by 2 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because pyocins are produced under stress conditions, and treatment with Mitomycin C (as DNA-damaging) can further activate their production [ 32 , 62 ]. The SOS response, triggered in stress conditions, stimulates RecA's protease activity, leading to the deactivation of PrtR, the negative regulator of PrtN, which is the activator of pyocin gene expression [ 63 – 65 ].…”

Section: Discussionmentioning

confidence: 99%

Assessment of bacteriocin production by clinical Pseudomonas aeruginosa isolates and their potential as therapeutic agents

Charkhian,

Soleimannezhadbari,

Bodaqlouei

et al. 2024

Microb Cell Fact

View full text Add to dashboard Cite

Introduction Bacterial infections and the rising antimicrobial resistance pose a significant threat to public health. Pseudomonas aeruginosa produces bacteriocins like pyocins, especially S-type pyocins, which are promising for biological applications. This research focuses on clinical P. aeruginosa isolates to assess their bacteriocin production, inhibitory spectrum, chemical structure, antibacterial agents, and preservative potential. Methods The identification of P. aeruginosa was conducted through both phenotypic and molecular approaches. The inhibitory spectrum and antibacterial potential of the isolates were assessed. The kinetics of antibacterial peptide production were investigated, and the activity of bacteriocin was quantified in arbitrary units (AU ml−1). Physico-chemical characterization of the antibacterial peptides was performed. Molecular weight estimation was carried out using SDS–PAGE. qRT-PCR analysis was employed to validate the expression of the selected candidate gene. Result The antibacterial activity of P. aeruginosa was attributed to the secretion of bacteriocin compounds, which belong to the S-type pyocin family. The use of mitomycin C led to a significant 65.74% increase in pyocin production by these isolates. These S-type pyocins exhibited the ability to inhibit the growth of both Gram-negative (P. mirabilis and P. vulgaris) and Gram-positive (S. aureus, S. epidermidis, E. hirae, S. pyogenes, and S. mutans) bacteria. The molecular weight of S-type pyocin was 66 kDa, and its gene expression was confirmed through qRT-PCR. Conclusion These findings suggest that S-type pyocin hold significant potential as therapeutic agents against pathogenic strains. The Physico-chemical resistance of S-type pyocin underscores its potential for broad applications in the pharmaceutical, hygiene, and food industries.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of bacteriocin production by clinical Pseudomonas aeruginosa isolates and their potential as therapeutic agents

Charkhian,

Soleimannezhadbari,

Bodaqlouei

et al. 2024

Microb Cell Fact

View full text Add to dashboard Cite

show abstract

“…From 1990 up to the present, the interest in these particles has continued, with the visualization of the dynamics of their production, explosive release and killing activity and studies of their regulation ( Matsui et al, 1993 ; Sun et al, 2014 ; Penterman et al, 2014b ; Fernandez et al, 2020 ; Vacheron et al, 2021 ; Bronson et al, 2022 ), their atomic structures and molecular mechanics ( Heymann et al, 2013 ; Ge et al, 2015 , 2020 ; Desfosses et al, 2019 ; Jiang et al, 2019 ; Fraser et al, 2021 ), their role in bacterial competition ( Heo et al, 2007 ; Waite and Curtis, 2009 ; Dorosky et al, 2017 , 2018 ; Oluyombo et al, 2019 ; Vacheron et al, 2021 ; Heiman et al, 2022 ) and their potential medical use ( Scholl and Martin, 2008 ; Scholl et al, 2009 ; Ritchie et al, 2011 ; Redero et al, 2020 ; Alqahtani et al, 2021 ; Six et al, 2021 ; Bhattacharjee et al, 2022 ) as well as their application as prophylactic or curative treatment against phytopathogens in agriculture ( Fernandez et al, 2017 ; Príncipe et al, 2018 ; Baltrus et al, 2022 ). Recent studies have also re-engineered eCIS structures to target new cell types and to deliver new proteins, opening new avenues for the usage of these particles ( Scholl, 2017 ; Bhattacharjee et al, 2022 ; Jiang et al, 2022 ; Kreitz et al, 2023 ).…”

Section: A Brief History Of Ecissmentioning

confidence: 99%

Evolutionary and ecological role of extracellular contractile injection systems: from threat to weapon

Heiman,

Vacheron,

Keel

2023

Front. Microbiol.

View full text Add to dashboard Cite

Contractile injection systems (CISs) are phage tail-related structures that are encoded in many bacterial genomes. These devices encompass the cell-based type VI secretion systems (T6SSs) as well as extracellular CISs (eCISs). The eCISs comprise the R-tailocins produced by various bacterial species as well as related phage tail-like structures such as the antifeeding prophages (Afps) of Serratia entomophila, the Photorhabdus virulence cassettes (PVCs), and the metamorphosis-associated contractile structures (MACs) of Pseudoalteromonas luteoviolacea. These contractile structures are released into the extracellular environment upon suicidal lysis of the producer cell and play important roles in bacterial ecology and evolution. In this review, we specifically portray the eCISs with a focus on the R-tailocins, sketch the history of their discovery and provide insights into their evolution within the bacterial host, their structures and how they are assembled and released. We then highlight ecological and evolutionary roles of eCISs and conceptualize how they can influence and shape bacterial communities. Finally, we point to their potential for biotechnological applications in medicine and agriculture.

show abstract

DNA Damage-Inducible Pyocin Expression Is Independent of RecA in xerC -Deleted Pseudomonas aeruginosa

Abstract: The opportunistic pathogen Pseudomonas aeruginosa produces pyocins—intraspecific, interbacterial killing complexes. The canonical pathway for pyocin production involves DNA damage and RecA activation.

Cited by 2 publications

References 23 publications

Assessment of bacteriocin production by clinical Pseudomonas aeruginosa isolates and their potential as therapeutic agents

Assessment of bacteriocin production by clinical Pseudomonas aeruginosa isolates and their potential as therapeutic agents

Evolutionary and ecological role of extracellular contractile injection systems: from threat to weapon

Contact Info

Product

Resources

About